ANX-M1 (Mouse IgG1)
Based on 1 Customer Validation
ANX-M1 Mouse IgG1 is a brain-penetrant C1q inhibitor. ANX-M1 Mouse IgG1 blocks classical complement pathway activation, reduces C1q concentrations in brain and plasma, and inhibits microglia-mediated synapse engulfment. ANX-M1 Mouse IgG1 can be used for the research of Huntington's disease, Alzheimer's disease, retinopathy and neuropathic pain.
For research use only. We do not sell to patients.
- Purity : 99.9%
- Molecular Weight:145.22 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Mouse IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human/Mouse
In Vitro
In Vivo
ANX-M1 Mouse IgG1 (7.5 μg/μL; intravitreal; single dose) reduces photoreceptor cell death, preserves retinal structure, and improves retinal function in a mouse model of photo-oxidative retinal degeneration[4].
ANX-M1 Mouse IgG1 (7.5 μg/μL; intravitreal; single dose) does not protect against photo-oxidative retinal degeneration in mice[4].
ANX-M1 Mouse IgG1 (100 mg/kg; intraperitoneal; 3 doses) inhibits serum complement activity but does not protect against photo-oxidative retinal degeneration in mice[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 J (adult, postnatal day 60-90, equal numbers of male and female, photo-oxidative damage-induced retinal degeneration)[4]
-
Dosage:7.5 μg/μL (1 μl volume per eye)
-
Administration:intravitreal; single dose
-
Result:Significantly reduced the number of TUNEL+ photoreceptor cells in the outer nuclear layer at day 14.
Significantly increased outer nuclear layer thickness (measured as rows of photoreceptor nuclei).
Significantly improved rod a-wave and b-wave electroretinography amplitudes, with the most pronounced differences at the highest flash intensity (1.9 log cd.s/m2).
Significantly increased cone electroretinography amplitudes.
Showed no significant difference in the number of IBA1+ microglia/macrophages in the outer retina and outer nuclear layer compared to control.\nShowed no significant differences in the number of TUNEL+ photoreceptor cells, outer nuclear layer thickness, number of IBA1+ microglia/macrophages in the outer retina, rod a-wave and b-wave electroretinography amplitudes, or cone electroretinography amplitudes at day 14 compared to control.
-
Animal Model:C57BL/6 J (adult, postnatal day 60-90, equal numbers of male and female, photo-oxidative damage-induced retinal degeneration)[4]
-
Dosage:100 mg/kg
-
Administration:intraperitoneal; 3 doses (day 0, day 4, day 8)
-
Result:Reduced serum complement activity by >50% compared to IgG isotype control at day 12.
Showed no significant differences in the number of TUNEL+ photoreceptor cells, outer nuclear layer thickness, number of IBA1+ microglia/macrophages in the outer retina, rod a-wave and b-wave electroretinography amplitudes, or cone electroretinography amplitudes at day 12 compared to control.
Gene ID
Accession
Target
C1q
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
ELISA, FACS, Functional assay
Verified Bioactivity
Chemical Information
-
Appearance Liquid
-
Molecular Weight 145.22 kDa
-
Color Colorless to light yellow
-
SMILES
[ANX-M1 (Mouse IgG1)]
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Phagocytosis Functional Assay
A phagocytosis functional assay measures the ability of phagocytic cells, such as neutrophils, macrophages, monocytes, or microglia/macrophages, to bind and internalize particulate targets including bacteria, yeast particles, beads, or myelin particles. Fluorescent flow-cytometry assays detect target uptake as fluorescence associated with gated phagocytes, while pH-sensitive dyes such as pHrodo increase signal in acidic phagosomal compartments and therefore preferentially report internalized particles rather than particles remaining outside the cell. Microscopy or high-content imaging can be used to confirm intracellular localization and, in some protocols, to follow uptake kinetics.
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Purity & Documentation
-
Data Sheet (264 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[2]. Hong S, et al. Complement and microglia mediate early synapse loss in Alzheimer mouse models. Science. 2016;352(6286):712-716. [Content Brief]
[3]. Yousefpour N, et al. Targeting C1q prevents microglia-mediated synaptic removal in neuropathic pain. Nat Commun. 2025;16(1):4590. Published 2025 May 17. [Content Brief]
[4]. Jiao H, et al. Subretinal macrophages produce classical complement activator C1q leading to the progression of focal retinal degeneration. Mol Neurodegener. 2018;13(1):45. Published 2018 Aug 20. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
ANX-M1 (Mouse IgG1) Related Classifications
HY-P992512 Related Classifications
Powered by Bioz